Sugi Predict

Sugi Predict / Targets / KLK14

KLK14

Kallikrein-14 · Q9P0G3 · KLK14 on Sugi Atlas →

1,838 patent compounds predicted against KLK14, 1,215 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL912875 SCHEMBL912875 0.85 11/20
SCHEMBL914380 SCHEMBL914380 0.69 11/20
SCHEMBL914283 SCHEMBL914283 0.73 10/20
SCHEMBL4202365 SCHEMBL4202365 0.73 10/20
SCHEMBL5387023 SCHEMBL5387023 0.59 10/20
SCHEMBL5791145 SCHEMBL5791145 0.58 10/20
SCHEMBL915741 SCHEMBL915741 0.59 9/20
SCHEMBL912869 SCHEMBL912869 0.57 9/20
SCHEMBL914390 SCHEMBL914390 0.43 9/20
SCHEMBL913416 SCHEMBL913416 1.00 8/20
SCHEMBL5793545 SCHEMBL5793545 0.67 8/20
SCHEMBL9984612 SCHEMBL9984612 0.64 8/20
SCHEMBL914043 SCHEMBL914043 0.61 8/20
SCHEMBL913630 SCHEMBL913630 0.60 8/20
SCHEMBL914160 SCHEMBL914160 0.60 8/20
SCHEMBL914308 SCHEMBL914308 0.58 8/20
SCHEMBL914010 SCHEMBL914010 0.57 8/20
SCHEMBL914131 SCHEMBL914131 0.54 8/20
SCHEMBL914127 SCHEMBL914127 0.51 8/20
SCHEMBL5790698 SCHEMBL5790698 0.64 7/20

Clinical trials — most relevant to KLK14 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
The Study to Reevaluate the Safety and Efficacy of Human Urinary Kallikrein PHASE4UNKNOWN
Kallikrein-kinin (KKS) and Renin-angiotensin-aldosterone System (RAAS) in Primary Aldosteronism PHASE4COMPLETED
Open-Label Safety, PK, and Efficacy Trial of Sebetralstat (KVD900) in Pediatric Patients (Ages 2-11) With HAE Type I or II PHASE3COMPLETED
Clinical Trial With Aprotinin in the Acute Respiratory Distress Syndrome Treatment PHASE3NOT_YET_RECRUITING
Lycopene in Treating Patients Undergoing Radical Prostatectomy for Prostate Cancer PHASE2COMPLETED
Safety and Efficacy of AGN-INM176 in Prostate Patients With Rising PSA PHASE1/PHASE2RECRUITING
Selenomethionine and Finasteride Before Surgery or Radiation Therapy in Treating Patients With Stage I or Stage II Prostate Cancer PHASE2COMPLETED
Immunotherapy With N 803, ETBX-071, and M-CENK in Combination With Radiation for Participants With High-Risk Prostate Cancer. PHASE2WITHDRAWN
A Study of TAK-188 in Adults With Advanced or Spreading Solid Tumors PHASE1/PHASE2RECRUITING
Evaluation to Assess Safety and Tolerability of DM199 in Subjects With Acute Ischemic Stroke PHASE2COMPLETED
Food Effect Study of Abiraterone Acetate for Treatment of Patients With Castration-Resistant Prostate Cancer PHASE2COMPLETED
Biological Therapy in Treating Patients With Primary or Advanced Glioma PHASE2SUSPENDED
Cilengitide in Treating Patients With Prostate Cancer PHASE2COMPLETED
Enzalutamide and PDS01ADC in PET Positive Recurrent Prostate Cancer (pprPC) Without Testosterone Lowering Therapy PHASE2RECRUITING
Cabozantinib (XL-184) Monotherapy for Advanced Cholangiocarcinoma PHASE2COMPLETED
Radiotherapy Plus Hormone Therapy in Biochemically-relapsing Prostate Cancer Patients Following Surgery PHASE1/PHASE2COMPLETED
Vaccination of Prostate Cancer Patients With MUC-2-KLH Conjugate Plus the Immunological Adjuvant QS21 PHASE1COMPLETED
A Phase I Clinical Study of a Single Dose of KLA480 PHASE1RECRUITING
A Phase I Single Ascending Dose Study of the Intravitreal Plasma Kallikrein Inhibitor KVD001 in Subjects With DME PHASE1COMPLETED
Inhibition of Plasma Kallikrein as a New Therapy for Lung Injury PHASE1UNKNOWN
Study to Assess PK, Safety and Tolerability in Healthy Subjects PHASE1COMPLETED
Study Investigating Intravesical HDAC Inhibition to Improve Response to Immuno-Oncology Agents PHASE1SUSPENDED
Dose-Seeking Trial of PCK3145 in Asymptomatic, Castrate Metastatic Prostate Cancer Patients. PHASE1COMPLETED
Phase Ib Feasibility Trial of Neoadjuvant Nivolumab/Lirilumab in Cisplatin-Ineligible Muscle-Invasive Bladder Cancer PHASE1COMPLETED
A Study of Alisertib (MLN8237) in Adult East Asian Participants With Advanced Solid Tumors or Lymphomas PHASE1COMPLETED
Urinary Kallikrein and Hypertension: A Prospective Study nanCOMPLETED
Stroke Risk Assessment and Markers of Blood Clotting in Patients With Newly Diagnosed Non-valvular Atrial Fibrillation (NVAF), Who Have Not Received Oral Anticoagulation Therapy (OAC-therapy) Prior to Inclusion nanRECRUITING
The Contact Activation System and Ulcerative Colitis nanCOMPLETED
Magnetic Resonance Imaging to Locate and Characterize Prostate Cancer nanCOMPLETED
Predicting Prostate Biopsy Results With Biomarkers and mpMRI. nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a KLK14 binder may also engage these)

ProteinNameSimilarity
Q7JIG6 — 0.982 Q7JIG6 →
Q9H2R5 — 0.982 Q9H2R5 →
P79204 — 0.981 P79204 →
KLK8 Kallikrein-8 0.980 landscape →
PRTN3 Myeloblastin 0.980 landscape →
Q61096 — 0.975 Q61096 →
Q61955 — 0.975 Q61955 →
P56435 — 0.974 P56435 →
Q8CGR5 — 0.974 Q8CGR5 →
Q9QYN3 — 0.973 Q9QYN3 →
P20718 — 0.973 P20718 →
P21842 — 0.972 P21842 →
P19236 — 0.971 P19236 →
Q9UBX7 — 0.970 Q9UBX7 →
P51124 — 0.969 P51124 →
O43240 — 0.969 O43240 →
KLK2 Kallikrein-2 0.969 landscape →
P52195 — 0.968 P52195 →
CMA1 Chymase 0.968 landscape →
KLK5 Kallikrein-5 0.968 landscape →
P15944 — 0.968 P15944 →
Q6UWY2 — 0.968 Q6UWY2 →
Q80WM7 — 0.968 Q80WM7 →
TPSD1 Tryptase delta (EC 3.4.21.59) (Delta-tryptase 0.966 landscape →
Q9XSM2 — 0.965 Q9XSM2 →
KLK7 Kallikrein-7 0.965 landscape →
Q6IE59 — 0.965 Q6IE59 →
O88780 — 0.965 O88780 →
KLK3 Prostate-specific antigen 0.964 landscape →
Q14B24 — 0.964 Q14B24 →